Latest IPPH Community News

Vanderbilt Institute for Population and Public Health20-Year Anniversary Symposium and ColloquiumMonday, November 2, 202612:00 – 5:30 PM

Celebrating 26 New MPH GraduatesAt Vanderbilt University School of Medicine’s Commencement on May 8, MPH Program Director Christiane Roumie, MD, MPH, and Executive Vice Dean Donald Brady, MD, celebrated the achievements of this year’s graduates. Seven students completed the Global Health track, 11 finished Epidemiology, and eight earned degrees in Health Policy. Honoring Dr. Bill Dupont’s Lasting Impact on the MPH Program

Epidemiology PhD ProgramThe Department of Epidemiology celebrated its PhD students and faculty at the annual recognition event on May 7. The event honored those who have shown excellence in research, leadership, and teaching, reflecting the department’s commitment to advancing public health through scholarship and mentorship.

Russell Rothman, MD, MPP, represented Vanderbilt as a featured speaker at the “Fireside Chat: C3TI Initiatives & Current Landscape” session during the workshop “Scaling Innovative Clinical Trial Approaches: Challenges, Progress, and Opportunities,” co-convened by the Duke-Margolis Institute for Health Policy and the U.S. Food and Drug Administration (FDA) CDER Center for Clinical Trial Innovation (C3TI).

A study published in Annals of Internal Medicine found that atrial fibrillation patients taking diltiazem with the blood thinners apixaban or rivaroxaban have a higher risk of serious bleeding than those using metoprolol. “These findings are particularly important at the population level,” said Ghadeer Dawwas, PhD, MBA, noting that in high-risk patients—especially at higher diltiazem doses—clinicians should carefully consider drug interactions, with metoprolol potentially representing a safer alternative.